The breast imaging market has been reinvigorated with an expanding arsenal of diagnostic and screening technologies for breast cancer. The recent FDA clearance of Fuji’s FCRm system, the anticipated arrival of new CR systems for mammography, not to mention GE’s newcomer — MR spectroscopy for breast — are positioned to fill the void left by FFDM and redefine breast imaging.
DMIST Sparks Trend in FFDM
If you enjoy this content, please share it with a colleague
- Read more about CR, MRS Refocus Breast Imaging
- Log in or register to post comments